文献速递精神分裂症与精神病性障碍

优化血浆氯氮平水平以改善治疗反应:个体患者数据荟萃分析与ROC曲线分析

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis.
PubMed 文献 · Br J Psychiatry · 2023-01-01

该研究基于9项研究、294例个体的患者水平数据,采用ROC曲线分析血浆氯氮平水平对治疗反应的预测性能。结果显示曲线下面积为0.612,最佳诊断获益点为372 ng/mL(敏感度57.3%,特异度65.7%),治疗反应的四分位距为223-558 ng/mL。作者建议氯氮平剂量应基于治疗药物监测优化,可推荐250-550 ng/mL范围,>350 ng/mL对反应最优。

要点

  • 血浆氯氮平水平对治疗反应预测的ROC曲线下面积为0.612。
  • 最佳诊断获益点氯氮平水平为372 ng/mL,敏感度57.3%,特异度65.7%。
  • 可推荐治疗范围250-550 ng/mL,>350 ng/mL对反应最优,>550 ng/mL需权衡不良反应风险。

核心结论

  • 氯氮平剂量应基于血药浓度优化,推荐范围250-550 ng/mL,>350 ng/mL对反应最优。
  • 部分患者可能需要>550 ng/mL才出现反应,但需权衡药物不良反应风险增加。

研究设计与样本

  • 系统检索PubMed、PsycINFO和Embase中提供氯氮平水平与反应个体参与者数据的研究。
  • 纳入9项研究共294例个体参与者,采用ROC曲线分析血浆氯氮平水平对治疗反应的预测性能。

主要发现

  • ROC分析曲线下面积为0.612。
  • 最佳诊断获益点氯氮平水平为372 ng/mL,此时反应敏感度57.3%,特异度65.7%。
  • 治疗反应的四分位距为223-558 ng/mL。
  • 混合模型纳入患者性别、年龄或试验时长未改善ROC性能。
  • 氯氮平剂量及浓度剂量比未对反应提供显著有意义的预测。

关键数值与推荐

  • 推荐氯氮平治疗水平范围250-550 ng/mL。
  • >350 ng/mL被认为对治疗反应最优。
  • 最佳诊断获益点372 ng/mL对应敏感度57.3%、特异度65.7%。

临床怎么用

  • 临床应基于治疗药物监测优化氯氮平剂量,而非仅依据固定剂量。
  • 可将250-550 ng/mL作为目标治疗范围,优先使水平>350 ng/mL。
  • 对水平>550 ng/mL者需权衡反应获益与不良反应风险增加。

局限性

  • ROC曲线下面积0.612提示预测性能有限。
  • 氯氮平剂量及浓度剂量比未显著预测反应。
  • 混合模型纳入性别、年龄或试验时长未改善预测性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although clozapine is the most efficacious medication for treatment-refractory schizophrenia, not all patients will have an adequate response. Optimising clozapine dose using therapeutic drug monitoring could therefore maximise response. AIMS: Using individual patient data, we undertook a receiver operating characteristic (ROC) curve analysis to determine an optimal therapeutic range for clozapine levels to guide clinical practice. METHOD: We conducted a systematic review of PubMed, PsycINFO and Embase for studies that provided individual participant level data on clozapine levels and response. These data were analysed using ROC curves to determine the prediction performance of plasma clozapine levels for treatment response. RESULTS: We included data on 294 individual participants from nine studies. ROC analysis yielded an area under the curve of 0.612. The clozapine level at the point of optimal diagnostic benefit was 372 ng/mL; at this level, the response sensitivity was 57.3%, and specificity 65.7%. The interquartile range for treatment response was 223-558 ng/mL. There was no improvement in ROC performance with mixed models including patient gender, age or length of trial. Clozapine dose and clozapine concentration to dose ratio did not provide significantly meaningful prediction of response to clozapine. CONCLUSIONS: Clozapine dose should be optimised based on clozapine therapeutic levels. We found that a range between 250 and 550 ng/mL could be recommended, while noting that a level of >350 ng/mL is the most optimal for response. Although some patients may not respond without clozapine levels >550 ng/mL, the benefits should be weighed against the increased risk of adverse drug reactions.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Northwood K, Pearson E, Arnautovska U, et al. Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis. Br J Psychiatry. 2023. PMID: 36994656. doi:10.1192/bjp.2023.27

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。